^
Phase 2
The First Affiliated Hospital of Xiamen University
Recruiting
Last update posted :
08/04/2022
Initiation :
06/15/2022
Primary completion :
06/15/2024
Completion :
06/15/2025
FAP
|
177Lu-DOTA-EB-FAPI • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Northwestern University
Not yet recruiting
Last update posted :
07/12/2022
Initiation :
07/22/2022
Primary completion :
07/15/2024
Completion :
07/15/2024
BRAF • CD4
|
BRAF V600E
|
vudalimab (XmAb717)
Phase N/A
Leiden University Medical Center
Recruiting
Last update posted :
04/11/2022
Initiation :
01/10/2022
Primary completion :
01/01/2024
Completion :
06/01/2024
TG
|
lenvatinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Alliance for Clinical Trials in Oncology
Active, not recruiting
Last update posted :
04/04/2022
Initiation :
10/01/2014
Primary completion :
01/28/2021
Completion :
08/06/2024
TG
|
sorafenib • everolimus
Phase 2
Academic and Community Cancer Research United
Active, not recruiting
Last update posted :
03/31/2022
Initiation :
05/04/2015
Primary completion :
07/17/2020
Completion :
12/31/2022
TG
|
Koselugo (selumetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Academic and Community Cancer Research United
Active, not recruiting
Last update posted :
01/06/2022
Initiation :
02/07/2018
Primary completion :
10/08/2022
Completion :
09/30/2024
ALB
|
Keytruda (pembrolizumab) • lenvatinib
Phase 2
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Recruiting
Last update posted :
12/01/2021
Initiation :
11/23/2020
Primary completion :
02/01/2022
Completion :
10/01/2022
TG
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • recombinant human thyroid stimulating hormone for injection (rhTSH)
Phase 2
Eisai Inc.
Completed
Last update posted :
11/24/2021
Initiation :
06/08/2017
Primary completion :
12/12/2019
Completion :
09/10/2020
TG
|
lenvatinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
07/15/2021
Initiation :
09/09/2010
Primary completion :
02/01/2020
Completion :
02/01/2020
BRAF • RAS • TG
|
RAS mutation
|
lenalidomide • Recentin (cediranib)
Phase 2
National University Hospital, Singapore
Recruiting
Last update posted :
03/05/2021
Initiation :
12/30/2020
Primary completion :
12/01/2021
Completion :
04/01/2022
TG
|
BRAF V600E • BRAF V600 • RAS mutation
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
01/26/2021
Initiation :
07/15/2019
Primary completion :
01/15/2022
Completion :
01/15/2022
ALB
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
04/03/2018
Initiation :
05/08/2013
Primary completion :
07/13/2015
Completion :
10/09/2017
BRAF • TG
|
Cabometyx (cabozantinib tablet)
Phase 4
Genzyme, a Sanofi Company
Completed
Last update posted :
03/23/2015
Initiation :
05/01/2012
Primary completion :
08/01/2012
Completion :
08/01/2012
TG
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
05/28/2014
Initiation :
10/01/2004
Primary completion :
08/01/2009
Completion :
08/01/2009
TG
|
Istodax (romidepsin)